Substance Dependence Treatment

Introduction to Substance Dependence Treatment

The American Academy of Family Physicians recommends that the optimal treatment for opioid dependence combines pharmacotherapy (buprenorphine/naloxone as first-line for outpatient care) with counseling and referral to specialized care, while for stimulant dependence (cocaine/amphetamines), the combination of contingency management (CM) and community reinforcement approach (CRA) is the most effective treatment 1, 2.

The American Academy of Family Physicians suggests that after a positive screening, a brief assessment should stratify patients into three categories with specific interventions 1.
For hazardous use, brief physician counseling is sufficient for this category 1, 3.
The American Academy of Family Physicians recommends using a motivational approach rather than a confrontational one 1.

The American Academy of Family Physicians states that buprenorphine/naloxone (Suboxone) is the preferred treatment for outpatient care due to its superior safety profile 3, 5.
Naloxone is poorly absorbed sublingually and prevents abuse by injection 3, 5.
Long-term maintenance treatment is indicated rather than rapid detoxification, which is associated with high relapse rates 3, 5.
Three FDA-approved medications are available: buprenorphine, naltrexone, and methadone (the latter limited to specialized programs) 5, 6.

The combination of CM and CRA is the most effective treatment with a number needed to treat (NNT) of 3.7 for abstinence 2.
CM involves providing rewards for negative urine samples 2.
CRA is a multi-level intervention including functional analysis, skills training, and social, family, recreational, and vocational reinforcements 2.
Currently, no FDA-approved medication is available specifically for methamphetamine use disorder 2, 7.

Using a motivational style rather than a confrontational one is essential for improving outcomes 1, 6.
Resisting the corrective reflex and helping patients generate their own arguments for healthy changes is recommended 3, 5.

Systematically evaluating comorbid mental illnesses and domestic violence is crucial 1, 4, 7.
Screening for depression, anxiety, and suicidal ideation is necessary 4, 7.

Offering harm reduction services to all patients who report stimulant use is recommended 7.
Services include naloxone distribution, safe use education, fentanyl test strips, and referral to needle exchange services 6, 7.